"China... has become a critical contributor to scientific innovation, advanced manufacturing, and global public health," Soriot said in a statement. China is AstraZeneca's second-largest market after the United States, where the company has recently invested heavily under pressure from President Donald Trump. "AstraZeneca's expansion and leadership in China will help the British manufacturer continue to grow -- supporting thousands of UK jobs," Starmer said in the statement shared by AstraZeneca. - US efforts -Britain's largest drugmaker has been making a recent shift towards the United States, which it hopes will account for half its global revenue by 2030. Separately, the White House has delayed for three years tariffs for AstraZeneca after it agreed to invest in US manufacturing capacity.